Impact of therapy on metabolic syndrome in young adult premenopausal female lupus patients: Beneficial effect of antimalarials

Arthritis Care and Research

Volumn 67, Issue 9, 2015, Pages 1255-1262

  Muniz, Luciana F ^a   Pereira, Rosa M R ^a   Silva, Thiago F ^a   Bonfá, Eloisa ^a   Borba, Eduardo F ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; APOLIPOPROTEIN B; C REACTIVE PROTEIN; CHLOROQUINE; CYCLOPHOSPHAMIDE; DOUBLE STRANDED DNA; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; METHYLPREDNISOLONE; PREDNISONE; TRIACYLGLYCEROL; GLUCOCORTICOID;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; DISEASE DURATION; DRUG EFFICACY; DRUG RESPONSE; DYSLIPIDEMIA; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOTHYROIDISM; KIDNEY DISEASE; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; PREMENOPAUSE; PREVALENCE; PROTEIN BLOOD LEVEL; PROTEINURIA; SEDENTARY LIFESTYLE; SLEDAI; SMOKING; SYSTEMIC LUPUS ERYTHEMATOSUS; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; BRAZIL; CHEMICALLY INDUCED; COMPLICATION; CROSS-SECTIONAL STUDY; FEMALE; LUPUS ERYTHEMATOSUS, SYSTEMIC; PROPENSITY SCORE;

ADULT; ANTIMALARIALS; BRAZIL; CHLOROQUINE; CROSS-SECTIONAL STUDIES; FEMALE; GLUCOCORTICOIDS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; METABOLIC SYNDROME X; PREDNISONE; PREMENOPAUSE; PREVALENCE; PROPENSITY SCORE;

EID: 84940116858     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22593     Document Type: Article

References (50)

1. Formiga F, Meco JF, Pinto X, Jacob J, Moga I, Pujol R., Lipid and lipoprotein levels in premenopausal systemic lupus erythematosus patients. Lupus 2001; 10: 359-63.
2. Negron AM, Molina MJ, Mayor AM, Rodriguez VE, Vila LM., Factors associated with metabolic syndrome in patients with systemic lupus erythematosus from Puerto Rico. Lupus 2008; 17: 348-54.
3. Elliot JR, Manzi S., Cardiovascular risk assessment and treatment in systemic lupus erythematosus. Best Pract Res Clin Rheumatol 2009; 23: 481-94.
4. Bruce IN, Urowitz MB, Gladman DD, Hallett DC., Natural history of hypercholesterolemia in systemic lupus erythematosus. J Rheumatol 1999; 26: 2137-43.
5. Bruce IN, Gladman DD, Urowitz MB., Premature atherosclerosis in systemic lupus erythematosus. Rheum Dis Clin N Am 2000; 26: 257-78.
6. Haque S, Mirjafari H, Bruce IN., Atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Curr Opin Lipidol 2008; 19: 338-43.
7. Parker B, Bruce IN., The metabolic syndrome in systemic lupus erythematosus. Rheum Dis Clin N Am 2010; 36: 81-97.
8. Telles RW, Lanna CC, Ferreira GA, Ribeiro AL., Metabolic syndrome in patients with systemic lupus erythematosus: association with traditional risk factors for coronary heart disease and lupus characteristics. Lupus 2010; 19: 803-9.
9. Zhang CY, Lu LJ, Li FH, Li HL, Gu YY, Chen SL, et al., Evaluation of risk factors that contribute to high prevalence of premature atherosclerosis in Chinese premenopausal systemic lupus erythematosus patients. J Clin Rheumatol 2009; 15: 111-6.
10. Bruce IN., " Not onlybut also": factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology (Oxford) 2005; 44: 1492-502.
11. Parker B, Urowitz MB, Gladman D, Lunt M, Bae SC, Sanches-Guerrero J, et al., Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Ann Rheum Dis 2013; 72: 1308-14.
12. Sabio JM, Vargas-Hitos J, Zamora-Pasadas M, Mediavilla JD, Navarrete N, Ramirez A, et al., Metabolic syndrome is associated with increased arterial stiffness and biomarkers of subclinical atherosclerosis in patients with systemic lupus erythematosus. J Rheumatol 2009; 36: 1-8.
13. Sidiropoulos PI, Karvounaris SA, Boumpas DT., Metabolic syndrome in rheumatic diseases: epidemiology, pathophysiology, and clinical implications. Arthritis Res Ther 2008; 10: 207.
14. Bellomio V, Spindler A, Lucero E, Berman A, Sueldo R, Berman H, et al., Metabolic syndrome in Argentinean patients with systemic lupus erythematosus. Lupus 2009; 18: 1019-25.
15. Pereira RM, Carvalho JF, Bonfa E., Metabolic syndrome in rheumatological diseases. Autoimmun Rev 2009; 8: 415-9.
16. Sabio JM, Zamora-Pasadas M, Jimenez-Jaimes J, Albadalejo F, Vargas-Hitos J, Rodriguez-del-Aguila MD, et al., Metabolic syndrome in patients with systemic lupus erythematosus from southern Spain. Lupus 2008; 17: 849-59.
17. Teede HJ, Lombard C, Deeks AA., Obesity, metabolic complications and menopause: an opportunity for prevention. Climacteric 2010; 13: 203-9.
18. Ebrahimpour P, Fakhrzadeh H, Heshmat R, Pourebrahim R, Larijani B., Metabolic syndrome and menopause: a population-based study. Diabetes Metab Syndr 2010; 4: 5-9.
19. Eshtiaghi R, Esteghamati A, Nakhjavani M., Menopause is an independent predictor of metabolic syndrome in Iranian women. Maturitas 2010; 65: 262-6.
20. Jouyandeh Z, Nayebzadeh F, Oorbani M,. Metabolic syndrome and menopause. J Diabetes Metab Disord 2013; 12: 1.
21. Parker B, Bruce IN., SLE and metabolic syndrome. Lupus 2013; 22: 1259-66.
22. Hochberg MC., Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
23. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001; 285: 2486-97.
24. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH., Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630-40.
25. Gladman DD, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al., The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 363-9.
26. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB., Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-47.
27. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, de Backer G, et al., Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987-1003.
28. The World Health Organization. Global database on body mass index: BMI classification. World Health Organization 2014. URL: http://apps.who.int/bmi/index.jsp?introPage=intro-3.html.
29. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al, and the International Diabetes Federation Task Force on Epidemiology and Prevention, National Heart, Lung, and Blood Institute, American Heart Association, World Heart Federation, International Atherosclerosis Society, and the International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention, National Heart, Lung, and Blood Institute, American Heart Association, World Heart Federation, International Atherosclerosis Society, and the International Association for the Study of Obesity. Circulation 2009; 120: 1640-5.
30. Mattews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC., Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.
31. Yokoyama H, Hirose H, Ohgo H, Saito I., Associations among lifestyle, serum adiponectin level and insulin resistance. Inter Med 2004; 43: 453-7.
32. Barros AJ, Hirakata VN., Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio. BMC Med Res Methodol 2003; 3: 21.
33. Austin PC., An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011; 46: 399-424.
34. Lanehart RE, Gil PR, Kim ES., Propensity score analysis and assessment of propensity score approaches using SAS procedures. SAS Global Forum, Statistics and Data Analysis 2012; 314: 1-11.
35. Royer M, Castelo-Branco C, Blumel JE, Chedraui PA, Danckers L, Bencosme A, et al., The US National Cholesterol Education Programme Adult Treatment Panel III (NCEP ATP III): prevalence of the metabolic syndrome in postmenopausal Latin American women. Climacteric 2007; 10: 164-70.
36. Barzilai N, Huffman DM, Muzumdar RH, Bartke A., The critical role of metabolic pathways in aging. Diabetes 2012; 61: 1315-22.
37. Alberti KG, Zimmet P, Shaw J., Metabolic syndrome: a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 2006; 23: 469-80.
38. Vadacca M, Margiotta D, Rigon A, Cacciapaglia F, Coppolino G, Amoroso A, et al., Adipokines and systemic lupus erythematosus: relationship with metabolic syndrome and cardiovascular disease risk factors. J Rheumatol 2009; 36: 295-7.
39. Parker B, Ahmad Y, Shelmerdine J, Edlin H, Yates AP, Teh LS, et al., An analysis of the metabolic syndrome phenotype in systemic lupus erythematosus. Lupus 2011; 20: 1459-65.
40. Chung PC, Avalos I, Oeser A, Gebretsadik T, Shintani A, Raggi P, et al., High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis 2007; 66: 208-14.
41. Howard G, O'Leary DH, Zaccaro D, Haffner S, Rewers M, Hamman R, et al, and The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Insulin sensitivity and atherosclerosis. Circulation 1996; 93: 1809-17.
42. Sada KE, Yamasaki Y, Maruyama M, Sugiyama H, Yamamura M, Maeshima Y, et al., Altered levels of adipocytokines in association with insulin resistance in patients with systemic lupus erythematosus. J Rheumatol 2006; 33: 1545-52.
43. Sachet JC, Borba EF, Bonfa E, Vinagre CG, Silva VM, Maranhao RC., Chloroquine increases low-density lipoprotein removal from plasma in systemic lupus patients. Lupus 2007; 16: 273-8.
44. Hage PM, Al-Badri MR, Azar ST., A favorable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti-inflammatory role. Ther Adv Endocrinol Metab 2014; 5: 77-85.
45. Borba EF, Bonfa E. Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J Rheumatol 2001; 28: 780-5.
46. Borba EF, Bonfa E. Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. Lupus 1997; 6: 533-9.
47. Carvalho JF, Bonfa E, Borba EF., Systemic lupus erythematosus and "lupus dyslipoproteinemia." Autoimmun Rev 2008; 7: 246-50.
48. Cardoso CR, Signorelli FV, Papi JA, Salles GF., Prevalence and factors associated with dyslipoproteinemias in Brazilian systemic lupus erythematosus patients. Rheumatol Int 2008; 28: 323-7.
49. Liu S, Han L, Guo J, Zheng ZH, Li H, Zhang L, et al., Metabolic syndrome in Chinese patients with systemic lupus erythematosus: no association with plasma cortisol level. Lupus 2013; 22: 519-26.
50. Cairoli E, Rebella M, Danese N, Garra V, Borba EF., Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect. Lupus 2012; 21: 1178-82.